Headache Horizons: New and Emerging Acute Migraine Treatments
A roadmap to navigating the acute migraine care landscape with 6 guideposts.
Peter McAllister, MD
09.14.20Lasmiditan Provided Freedom From Migraine Pain at 60 Minutes for as Long as 48 Hours
09.02.20Personalized Treatment Service Online for Individuals with Headache & Migraines
08.20.20Rimegepant for Acute Migraine Treatment Is Well Tolerated by Individuals Taking CGRP Monoclonals for Migraine Prevention
07.31.20Concussion Affects Driving Reaction Time—Even After Symptoms are Gone
07.29.20Atogepant Phase 3 Clinical Trial Shows Reduction in Monthly Migraines
Neurologists need to have a palliative care skill set.
Jessica M. Baker, MD
Headache Horizons: The Hateful Eight
The mind keeps score with trauma, pain syndromes, and headache.
Peter McAllister, MD
07.17.20Remote Electrical Neurostimulation Provides Significant Pain Relief in Chronic Migraine
06.23.20FDA Grants Premarket Approval for Neurostimulation System for Chronic Back Pain
06.17.20Galcanezumab Reduces Episodic and Chronic Migraine Pain Burden
06.16.20National Headache Foundation Survey Shows People With Migraine Feel Misunderstood
06.15.20Eptinezumab Reduced Use of Acute Migraine Treatments and Resolved Medication Overuse Headache
06.11.20Dihydroergotamine Delivered to Upper Nasal Cavity is Safe and Effective for Acute Migraine Treatment
06.08.20Phase 2 Clinical Trial of LSD for Cluster Headaches Initiated
Teleneurology Billing and Coding
Perspectives on coding evaluation & management during the COVID-19 pandemic.
Brad Klein, MD, MBA, FAAN, FAHS, FAANEM, and Raissa Villanueva MD, MPH, FAAN
Something can almost always be offered virtually for people with neuro-ophthalmologic conditions.
Melissa W. Ko, MD; Kevin E. Lai, MD; and Devin D. Mackay, MD
Teleneurology for Primary Headache Disorders
During the COVID-19 public health emergency, remote and in-person care for headache disorders is necessary to reduce patient risk.
Jennifer Robblee, MD, MSc; Amaal J. Starling, MD; Rashmi B. Halker Singh, MD, FAHS, FAAN; and Nina Riggins, MD, PhD
Chief Medical Editor's Page
COVID-19: A Tele- All Exposé
Stephen M. Gollomp, MD, and Paul G. Mathew, MD, DNBPAS, FAAN, FAHS
05.21.20FDA Approves Dihydroergotamine Mesylate Nasal Spray With Competitive Generic Therapy Designation